← Back to Screener
Calidi Biotherapeutics, Inc. (CLDI)
Price$0.28
Favorite Metrics
Price vs S&P 500 (26W)-86.97%
Price vs S&P 500 (4W)-15.62%
Market Capitalization$2.95M
All Metrics
Book Value / Share (Quarterly)$0.52
P/TBV (Annual)1.78x
Cash Flow / Share (Quarterly)$-2.97
Price vs S&P 500 (YTD)-79.51%
EPS (TTM)$-5.81
10-Day Avg Trading Volume1.38M
EPS Excl Extra (TTM)$-5.81
EPS (Annual)$-65.49
ROI (Annual)2.62%
Cash / Share (Quarterly)$0.78
ROA (Last FY)-291.61%
EBITD / Share (TTM)$-4.30
Cash Flow / Share (Annual)$-2.97
P/B Ratio0.78x
P/B Ratio (Quarterly)2.23x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-26.32x
ROA (TTM)-168.33%
EPS Incl Extra (Annual)$-65.49
Current Ratio (Annual)1.59x
Quick Ratio (Quarterly)1.48x
3-Month Avg Trading Volume0.33M
52-Week Price Return-94.81%
Tangible BV / Share (Quarterly)$3.16
52-Week High$19.20
EPS Excl Extra (Annual)$-65.49
CapEx CAGR (5Y)-19.32%
26-Week Price Return-82.98%
Quick Ratio (Annual)1.48x
13-Week Price Return-75.84%
Total Debt / Equity (Annual)0.23x
Current Ratio (Quarterly)1.59x
Enterprise Value$-1.77
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.78
3-Month Return Std Dev120.81%
Net Income / Employee (TTM)$-1
ROE (Last FY)2.80%
Net Interest Coverage (Annual)-58.21x
EPS Basic Excl Extra (Annual)$-65.49
P/FCF (TTM)47.14x
Total Debt / Equity (Quarterly)0.23x
EPS Incl Extra (TTM)$-5.81
ROI (TTM)-315.69%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.77
Price vs S&P 500 (52W)-124.64%
Year-to-Date Return-76.87%
5-Day Price Return5.05%
EPS Normalized (Annual)$-65.49
Month-to-Date Return13.22%
Cash Flow / Share (TTM)$-0.66
EBITD / Share (Annual)$-62.18
LT Debt / Equity (Annual)0.16x
LT Debt / Equity (Quarterly)0.16x
EPS Basic Excl Extra (TTM)$-5.81
P/TBV (Quarterly)2.12x
P/B Ratio (Annual)2.23x
Book Value / Share (Annual)$0.52
Price vs S&P 500 (13W)-76.53%
Beta1.56x
P/FCF (Annual)675.84x
ROE (TTM)-410.81%
52-Week Low$0.21
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.29
4.29
4.29
4.29
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CLDICalidi Biotherapeutics, Inc. | — | — | — | — | $0.28 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Calidi Biotherapeutics is a clinical-stage immuno-oncology company developing allogeneic stem cell therapies that deliver oncolytic viruses to treat cancer. Its pipeline includes CLD-101 for high-grade gliomas, CLD-201 for solid tumors, and CLD-400 for lung cancer and metastatic tumors, with CLD-301 in discovery research.